TrialNeuro-oncology2018

Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.

Andrew Brenner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.